Impact of Schizophrenia on Outcomes Following Non-Invasive Ventilation for Acute Hypercapnic Respiratory Failure in COPD
- 1Department of Respiratory Medicine, Sengkang General Hospital, Singapore
- 2Department of Respiratory & Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
- 3Discipline of Psychiatry and Mental Health, University of New South Wales, NSW, Australia
Abstract
Objective Limited data describe outcomes in people with comorbid schizophrenia when admitted with acute hypercapnic respiratory failure (AHRF). This study compared outcomes in people with COPD requiring non-invasive ventilation (NIV), with and without schizophrenia, to identify priorities for intervention and research.Methods This is a retrospective cohort study from a single Australian quaternary referral hospital of people with COPD requiring NIV for AHRF over 5 years from 1 January 2017 to 31 December 2024, excluding admissions between 1 January 2020 and 31 December 2022, when the COVID-19 pandemic disrupted usual practices. Primary outcomes were length of stay (LOS) and NIV duration (days). Secondary outcomes included NIV discontinuation reason, challenges to NIV and readmission. Descriptive and comparative statistics summarised variables by schizophrenia status and assessed between-group differences. Cox proportional hazards models assessed survival, while association between schizophrenia and readmission was analysed using competing-risks regression.Results Prevalence of schizophrenia is higher in this cohort than general population, comprising 36 (19%) of 186 individuals, and 97 (30%) of 328 admissions. Those with schizophrenia were younger (66.6 vs. 72.5 years, p = 0.001), with more current smokers (75% vs. 42.7%, p = 0.005) and had admissions with shorter LOS (6 vs. 9 days, p = 0.043) and NIV duration (3 vs. 5 days, p = 0.021). There was no significant difference in reason for NIV discontinuation between the groups. Readmission rates were higher in the schizophrenia group (44.4% vs. 24.0%, p = 0.025). Age at death was lower for those with schizophrenia (67.3 vs. 77.4 years, p < 0.001).Conclusion People with schizophrenia had shorter LOS and NIV use, higher readmission rates, higher prevalence of current smokers and younger age at presentation and death. These findings suggest that schizophrenia is an at-risk subgroup in AHRF, highlighting the need for collaborative action.
Related
- Respiratory health outcomes following co-exposure to subchronic high temperature, episodic wildfire smoke exposure, and high-cholesterol diet
- Refractory Anti-HMGCR Necrotizing Myopathy With Progressive Hypercapnic Respiratory Failure Responsive to a JAK Inhibitor.
- Nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as initial respiratory support during minimally invasive surfactant therapy in preterm infants with respiratory distress syndrome: a retrospective real-world cohort study
- Global Protective Ventilator Settings Are Not Regional Protection: A Compartment-Resolved Framework for Personalizing Mechanical Ventilation in Acute Respiratory Distress Syndrome
- Combined Approach with Ultrasound and Pressure–Volume Loops to Manage Mechanical Ventilation in Acute Hypoxemic Respiratory Failure
BibTeX
@article{soh2026impact,
title = {{Impact of Schizophrenia on Outcomes Following Non-Invasive Ventilation for Acute Hypercapnic Respiratory Failure in COPD}},
author = {Rui Ya Soh and Sanjay Farshid and Hayden Venville and Elizabeth Lambrinos and Keith Wong and Collette Menadue and Julia Lappin and Amanda J. Piper and Brendon Yee and Olivia A. McGuiness},
journal = {COPD},
year = {2026},
month = oct,
doi = {10.1080/15412555.2026.2754645},
url = {https://doi.org/10.1080/15412555.2026.2754645},
note = {CC BY},
}
RIS
TY - JOUR
TI - Impact of Schizophrenia on Outcomes Following Non-Invasive Ventilation for Acute Hypercapnic Respiratory Failure in COPD
AU - Rui Ya Soh
AU - Sanjay Farshid
AU - Hayden Venville
AU - Elizabeth Lambrinos
AU - Keith Wong
AU - Collette Menadue
AU - Julia Lappin
AU - Amanda J. Piper
AU - Brendon Yee
AU - Olivia A. McGuiness
PY - 2026
DA - 2026/10/01
JO - COPD
DO - 10.1080/15412555.2026.2754645
UR - https://doi.org/10.1080/15412555.2026.2754645
AB - Objective Limited data describe outcomes in people with comorbid schizophrenia when admitted with acute hypercapnic respiratory failure (AHRF). This study compared outcomes in people with COPD requiring non-invasive ventilation (NIV), with and without schizophrenia, to identify priorities for intervention and research.Methods This is a retrospective cohort study from a single Australian quaternary referral hospital of people with COPD requiring NIV for AHRF over 5 years from 1 January 2017 to 31 December 2024, excluding admissions between 1 January 2020 and 31 December 2022, when the COVID-19 pandemic disrupted usual practices. Primary outcomes were length of stay (LOS) and NIV duration (days). Secondary outcomes included NIV discontinuation reason, challenges to NIV and readmission. Descriptive and comparative statistics summarised variables by schizophrenia status and assessed between-group differences. Cox proportional hazards models assessed survival, while association between schizophrenia and readmission was analysed using competing-risks regression.Results Prevalence of schizophrenia is higher in this cohort than general population, comprising 36 (19%) of 186 individuals, and 97 (30%) of 328 admissions. Those with schizophrenia were younger (66.6 vs. 72.5 years, p = 0.001), with more current smokers (75% vs. 42.7%, p = 0.005) and had admissions with shorter LOS (6 vs. 9 days, p = 0.043) and NIV duration (3 vs. 5 days, p = 0.021). There was no significant difference in reason for NIV discontinuation between the groups. Readmission rates were higher in the schizophrenia group (44.4% vs. 24.0%, p = 0.025). Age at death was lower for those with schizophrenia (67.3 vs. 77.4 years, p < 0.001).Conclusion People with schizophrenia had shorter LOS and NIV use, higher readmission rates, higher prevalence of current smokers and younger age at presentation and death. These findings suggest that schizophrenia is an at-risk subgroup in AHRF, highlighting the need for collaborative action.
SN - 1541-2563
SN - 1541-2555
ER -